Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mesoblast Seeks FDA Meeting on Accelerated Approval Path for Revascor
Details : Revascor (rexlemestrocel-L) is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells and a Phase 3 candidate being developed for both advanced and end-stage CHF.
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants RMAT Designation for Revascor® in Children with Heart Disease
Details : Revascor (rexlemestrocel-L) is preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is being evaluated for the treatment of children with hypoplastic left heart syndrome.
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revascor Improves Survival in High-Risk Ischemic Heart Failure with Inflammation
Details : Revascor (rexlemestrocel-L) is preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is being evaluated for the treatment of children with hypoplastic left heart syndrome.
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apolipoprotein A-I, Human
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CSL Announces Top-Line Results from Phase 3 AEGIS-II Trial of CSL112
Details : CSL112 (apolipoprotein A-I [human]) is an investigational cholesterol efflux enhancer under development for treating acute myocardial infarction.
Product Name : CSL112
Product Type : Protein
Upfront Cash : Inapplicable
November 02, 2024
Lead Product(s) : Apolipoprotein A-I, Human
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revascor (rexlemestrocel-L) reverses inflammation-related endothelial dysfunction and reduces adverse clinical outcomes across the spectrum of HFrEF patients. It is in development for advanced chronic heart failure and chronic low back pain.
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revascor (rexlemestrocel-L), an immunomodulatory therapy address high degree of inflammation in heart and in circulation that is present across spectrum of HFrEF patients, class II through end-stage CHF, in order to reduce high rate of major cardiac even...
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mesoblast's landmark DREAM-HF randomized controlled Phase 3 trial results showed that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths.
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Stroke Patient Treated with Afamelanotide
Details : The CUV801 study is evaluating the use of afamelanotide in six patients who suffered an acute stroke, with a main focus on safety monitoring following drug administration as they are admitted to hospital.
Product Name : Scenesse
Product Type : Peptide
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Afamelanotide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analysis of Revascor (Rexlemestrocel-L) in patients with chronic heart failure and low ejection fraction showed greatest treatment benefit in major adverse events of cardiovascular mortality or irreversible morbidity in patients with diabetes or myocardi...
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 12, 2021
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $110.0 million
Deal Type : Financing
Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
Details : Funds will be used in advancing manufacturing and development of rexlemestrocel-L platform to meet commercial objectives for chronic heart failure and chronic low back pain due to degenerative disc disease following the recent completion of Phase 3 trial...
Product Name : Revascor
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 03, 2021
Lead Product(s) : Rexlemestrocel-L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $110.0 million
Deal Type : Financing